Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

GlaxoSmithKline (GSK - Analyst Report) recently announced that it has entered into an agreement with a South African pharma company, Aspen Group, to divest two thrombosis products, Fraxiparine and Arixtra, and the related manufacturing site at the Notre-Dame de Bondeville. The deal is valued at £0.7 billion in cash, of which £0.1 billion pertains to inventory.

As per the terms of the agreement, Aspen will acquire worldwide rights to Arixtra and Fraxiparine in all territories excluding China, India and Pakistan. However, Glaxo will continue to distribute and market the products under license from Aspen in Indonesia. Glaxo is expected to transfer the majority of assets related to Arixtra and Fraxiparine by the end of 2013 and the manufacturing site in the first half of 2014.

The move was not unexpected. On the second quarter conference call, Glaxo revealed that it has received an offer from Aspen Group for Fraxiparine and Arixtra, and the related manufacturing site.

The net proceeds from the transaction, expected to be approximately £0.6 billion, will not have an impact on Glaxo’s 2013 earnings.

We believe the deal is in line with Glaxo’s long-term strategy. Glaxo has been streamlining its Consumer Healthcare business segment for some time now. In Sep 2013, Glaxo entered into an agreement with a Japanese consumer goods company, Suntory Beverage & Food Ltd., to divest its nutritional drinks brands, Lucozade and Ribena, for £1.35 billion in cash. The deal is expected to close by the end of this year.

Earlier, Glaxo had divested its non-core Consumer Healthcare over-the-counter products primarily in the U.S. and Europe. Total annual sales of these products amounted to approximately £500 million. Glaxo divested these products with the intention of channeling its focus on priority brands and markets.

We believe that Glaxo will work on streamlining its operations further.

Glaxo, a large cap pharma company, carries a Zacks Rank #3 (Hold). At present, large-cap pharma companies like Roche (RHHBY - Analyst Report), Novo Nordisk (NVO - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report) look well-positioned. While Roche is a Zacks Ranked #1 (Strong Buy) stock, Novo Nordisk and Bayer carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%